Hyperaldosteronism Clinical Presentation

  • Author: George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London); Chief Editor: Stephen Kemp, MD, PhD   more...
 
Updated: May 10, 2012
 

History

Primary hyperaldosteronism may be asymptomatic, particularly in its early stages. When symptoms are present, they may be related to hypertension (if severe), hypokalemia, or both.

The spectrum of hypertension-related symptoms includes the following:

  • Headaches
  • Facial flushing
  • If hypertension is severe, weakness, visual impairment, impaired consciousness, and seizures (hypertensive encephalopathy)

Hypokalemia can be precipitated by non–potassium-sparing diuretics or sodium loading. Symptoms of hypokalemia include the following:

  • Constipation
  • Polyuria and polydipsia (because of impaired renal concentrating ability)
  • Weakness
  • If the serum potassium is low enough, paralysis and disturbances of cardiac rhythm[5]

Hyperglycemia or frank diabetes mellitus is possible because insulin secretion is a potassium-dependent process that may be impaired by hypokalemia.

If secondary hyperaldosteronism is suspected as the cause of hypertension, the history should include questions about flushing, diaphoresis, anxiety attacks, and headaches (pheochromocytoma) and about hematuria and abdominal fullness (Wilms tumor or other renal tumor), in addition to the above symptoms.[6, 7]

For patients in whom secondary hyperaldosteronism is suggested, questions should be specifically directed at potential causes (eg, the presence and duration of swelling, the child’s exercise tolerance).

Information should be sought about a family history of essential hypertension and familial syndromes, including the following:

  • Neurofibromatosis (associated with renal artery stenosis and pheochromocytoma)
  • Multiple endocrine neoplasia (MEN) type 2 – This includes MEN 2A (parathyroid adenoma, medullary thyroid carcinoma [MTC], and pheochromocytoma) and MEN 2B (mucosal neuromas of eyelids, lips, and tongue with a long thin face, pheochromocytoma, and MTC)
  • von Hippel-Lindau syndrome - Cerebellar hemangioblastoma; renal and pancreatic cysts and carcinoma; hemangiomas of the retina, liver, and adrenal glands; and pheochromocytomas
Next

Physical Examination

In any child or adolescent with significant hypertension, a thorough investigation into the cause is warranted. Hypermineralocorticoidism should be considered in any patient with associated hypokalemia, though it should not be excluded in the absence of hypokalemia. In patients with significant hypertension, blood pressure should be measured several times, preferably with an automated device after a supine rest.

Examination of the hypertensive patient should include the following:

  • General examination – Be alert for dysmorphic features (eg, MEN 2B), evidence of neurofibromatosis type 1 (NF-1; ie, café-au-lait lesions, axillary freckling, short stature, and evidence of disease in parents), and features of Cushing syndrome (ie, obesity, short stature, striae, and hirsutism)
  • Neck examination – Assess for a thyroid mass (MTC associated with MEN 2)
  • Cardiovascular examination - Assess left ventricular muscle mass and exclusion of murmurs and pulse differential (eg, coarctation of the aorta); check for abdominal bruits (renal artery stenosis) and peripheral edema (secondary hyperaldosteronism)
  • Abdominal examination – Look for masses (Wilms tumor), hepatomegaly (cardiac failure or liver disease), splenomegaly, and ascites
  • Neurologic examination - Examine the eyes, and assess visual acuity (severe hypertension may interfere with vision); examine the eye grounds (looking for retinal angiomas [von Hippel-Lindau syndrome]); be alert for hypertensive retinopathy, which is of prognostic significance, including arterial narrowing, hemorrhages, cotton-wool spots, and papilledema; assess for Lisch nodules of the iris (NF-1)
  • Strength assessment - Evaluation for weakness, focal neurologic signs, or impaired conscious state in a patient with severe hypertension, which requires urgent treatment and central nervous system (CNS) imaging to exclude infarction or hemorrhage
  • Skin examination - In patients who have secondary hyperaldosteronism, look for evidence of NF-1
Previous
Next

Complications

The main complications of primary hyperaldosteronism are hypertension and hypokalemia.

Hypertension due to hyperaldosteronism can damage many organs and organ systems, including the heart (hypertrophy and myocardial fibrosis), the blood vessels (vascular remodeling with medial and intimal hypertrophy and acceleration of atherogenesis), the eyes (arterial narrowing, retinal ischemia, and papilledema), the kidneys (progressive deterioration with nephrosclerosis), and the brain (hemorrhage). Aggressive blood pressure control and early diagnosis and treatment of the underlying hyperaldosteronism minimize the risk.

Hypokalemia initially results in weakness, constipation, and polyuria; when it is more severe, it may cause cardiac arrhythmias. Patients receiving cardiac drugs are at greater risk for this complication.

Previous
 
 
Contributor Information and Disclosures
Author

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London)  Professor and Chair, First Department of Pediatrics, Athens University Medical School, Aghia Sophia Children's Hospital, Greece; UNESCO Chair on Adolescent Health Care, University of Athens, Greece

George P Chrousos, MD, FAAP, MACP, MACE, FRCP(London) is a member of the following medical societies: American Academy of Pediatrics, American College of Endocrinology, American College of Physicians, American Pediatric Society, American Society for Clinical Investigation, Association of American Physicians, Endocrine Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Coauthor(s)

Antony Lafferty, MB ChB, FRACP  Senior Lecturer of Pediatric Endocrinology, Monash University Department of Pediatrics, National Institutes of Health, Bethesda, MD, and Princess Margaret Hospital for Children, Perth, Western Australia

Antony Lafferty, MB ChB, FRACP is a member of the following medical societies: Endocrine Society

Disclosure: Nothing to disclose.

Chief Editor

Stephen Kemp, MD, PhD  Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Pediatric Endocrine Society, and Society for Pediatric Research

Disclosure: Pfizer Grant/research funds P.I.; Tercica Grant/research funds Other; Eli Lily Grant/research funds PI; NovoNordisk Grant/research funds PI; NovoNordisk Consulting fee Consulting; Onyx Heart Valve Consulting fee Consulting

Thomas A Wilson, MD Professor of Clinical Pediatrics, Chief and Program Director, Division of Pediatric Endocrinology, Department of Pediatrics, The School of Medicine at Stony Brook University Medical Center

Thomas A Wilson, MD is a member of the following medical societies: Endocrine Society, Pediatric Endocrine Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Funder JW. The genetic basis of primary aldosteronism. Curr Hypertens Rep. Apr 2012;14(2):120-4. [Medline].

  2. Escher G. Hyperaldosteronism in pregnancy. Ther Adv Cardiovasc Dis. Apr 2009;3(2):123-32. [Medline].

  3. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension. Sep-Oct 1984;6(5):717-23. [Medline].

  4. Ignatowska-Switalska H, Chodakowska J, Januszewicz W, Feltynowski T, Adamczyk M, Lewandowski J. Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. J Hum Hypertens. Jun 1997;11(6):373-8. [Medline].

  5. Kasifoglu T, Akalin A, Cansu DU, Korkmaz C. Hypokalemic paralysis due to primary hyperaldosteronism simulating Gitelman's syndrome. Saudi J Kidney Dis Transpl. Mar 2009;20(2):285-7. [Medline].

  6. Künzel HE. Psychopathological symptoms in patients with primary hyperaldosteronism--possible pathways. Horm Metab Res. Mar 2012;44(3):202-7. [Medline].

  7. Schmiemann G, Gebhardt K, Hummers-Pradier E, Egidi G. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J Am Board Fam Med. Jan-Feb 2012;25(1):98-103. [Medline].

  8. Gordon RD. Primary aldosteronism. J Endocrinol Invest. Jul-Aug 1995;18(7):495-511. [Medline].

  9. Gordon RD, Stowasser M, Klemm SA, Tunny TJ. Primary aldosteronism--some genetic, morphological, and biochemical aspects of subtypes. Steroids. Jan 1995;60(1):35-41. [Medline].

  10. Spence JD. Diagnosis of primary aldosteronism: for medical management, not just surgery. J Hypertens. Jan 2009;27(1):204-5; author reply 205. [Medline].

Previous
Next
 
Steroid biosynthetic pathway.
Physiologic regulation of the renin-angiotensin-aldosterone axis.
Table. Drugs Used in the Management of Idiopathic Hyperaldosteronism in Children
Drug Class Pediatric Dose
SpironolactoneAldosterone antagonist0-10 kg: 6.25 mg/dose PO q12h



11-20 kg: 12.5 mg/dose PO q12h



21-40 kg: 25 mg/dose PO q12h



>40 kg: 25 mg PO q8h



Potassium canrenoateAldosterone antagonist3-8 mg/kg IV qd; not to exceed 400 mg
AmiloridePotassium-sparing diuretic0.2 mg/kg q12h
TriamterenePotassium-sparing diuretic2 mg/kg/dose q8-24h
NifedipineDihydropyridine calcium channel antagonist0.25-0.5 mg/kg PO q6-8h
AmlodipineCalcium channel antagonist0.05-0.2 mg/ day PO
DoxazosinAlpha1 -specific adrenergic antagonist0.02-0.1 mg/day; not to exceed 4 mg
PrazosinAlpha1 -specific adrenergic antagonist0.005 mg/kg test dose, then 0.025-0.1 mg/kg/dose q6h; not to exceed 0.5 mg/dose
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.